Sangamo Hopes to Corner Zinc Finger Market with Acquisition of Gendaq | GenomeWeb

NEW YORK, May 31 - Sangamo Biosciences's acquisition of Gendaq will allow the company to corner the market on zinc finger protein technology as well as to stave off any potential patent disputes, company executives said Thursday.

"Gendaq really represents the one piece of scientific thinking that was not part of our family," Casey Case, Sangamo's vice president for research, told GenomeWeb. "It's great to have them in the fold."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.